Cancer Groups Aim to Broaden Clinical Trial Participant Pool

Feb. 9, 2021, 8:27 PM

Cancer patients who are between treatments or are taking medications for other conditions wouldn’t automatically be left out of clinical trials under a proposal by advocacy groups to broaden the study population.

Five new recommendations published Tuesday by Friends of Cancer Research and the American Society of Clinical Oncology aim to remove hurdles to enrollment by better tailoring the criteria for who can participate in the study at hand.

Eligibility criteria transfer from study to study, sometimes in ways that make it harder for minorities or women to participate. Jeff Allen, president and CEO of Friends, noted the range of lab ...

To read the full article log in.

Learn more about A Bloomberg Law subscription.